We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Emerging Technologies Boost European IVD Markets

By Labmedica staff writers
Posted on 07 Nov 2006
The emergence and widening adoption of new technologies are boosting the revenue prospects of European in vitro diagnostics (IVD) markets.

Frost & Sullivan (Palo Alto, CA, USA), a global growth-consulting company, reported that the European IVD markets earned revenues of U.S.$6.60 billion in 2005 and estimates they will reach U.S.$9.95 billion in 2012.

"The adoption of new technologies, such as molecular and point-of-care testing, combined with the increasing trend towards laboratory automation will drive growth in the European IVD markets,” noted Frost & Sullivan research associate A.K. More...
Arun. "An emphasis on providing high quality healthcare and ensuring timely diagnosis is driving the adoption of these clinical tests and automated solutions while promoting market growth.”

Emerging markets such as molecular testing and near testing are supporting established segments such as clinical chemistry and hematology, thereby spurring market expansion. Moreover, labor shortages are pressurizing clinical laboratories to adopt high throughput and modular solutions, reinforcing growth in the market.

However, challenges still exist in the industry. Demographic changes combined with new diseases are compelling IVD manufacturers to increase their R&D investments. At the same time, competition has led to price erosion, squeezing revenue returns for market participants. In addition, the growing popularity of emerging segments could overshadow mature segments in the market.

A focused strategy will be vital for IVD manufacturers to ensure sufficient returns on investment. In the present market scenario, approaches centering on competitive pricing, new and innovative products, a broad product portfolio, and novel technologies will allow companies to gain a competitive edge.



Related Links:
Frost & Sullivan

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.